Facilitated By

San Antonio Medical Foundation

A Phase 3, Randomized, Study To Assess The Efficacy And Safety Of Ublituximab In Combination With Ibrutinib Compared To Ibrutinib Alone, In Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
Geneva
Research Start Date
Status
Active

This is a Phase 3 Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with Ibrutinib Compared to Ibrutinib Alone, in Patients with Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL). Will evaluate the effect of the addition of ublituximab to ibrutinib on overall response rate (ORR = CR + PR) in all study patients who are evaluable for efficacy assessment after the 200th study patient is enrolled across all sites.

Collaborative Project
Clinical Care
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.